| Crude incidence (%)b | OR (95% CI)c | Marginal effect (%)b | ||
---|---|---|---|---|---|
SSRI/SNRI | Psychotherapy | Crude | Adjusted | ||
Main analysis: SSRI/SNRI vs. psychotherapy | 16.4 | 11.8 | 1.46 (0.97, 2.20) | 1.36 (1.06, 1.74)a | 31.0 (6.6, 55.3)a |
Subgroup analysis stratified by | |||||
Age | |||||
 < 65 years | 14.5 | 12.6 | 1.18 (0.75, 1.87) | 1.23 (0.93, 1.62) | 20.6 (-6.6, 47.7) |
 ≥ 65 years | 19.3 | 9.1 | 2.38 (1.05, 5.41)a | 1.73 (1.09, 2.75)a | 54.6 (10.2, 98.9)a |
Sex | |||||
 Male | 17.5 | 13.0 | 1.42 (0.81, 2.50) | 1.34 (0.95, 1.90) | 29.5 (-3.5, 62.4) |
 Female | 15.9 | 11.1 | 1.52 (0.91, 2.54) | 1.38 (1.02, 1.86)a | 32.3 (3.2, 61.5)a |
Race | |||||
 White | 15.0 | 8.9 | 1.81 (1.00, 3.27) | 1.48 (1.10, 1.98)a | 38.7 (12.1, 65.4)a |
 Black | 18.1 | 17.6 | 1.04 (0.62, 1.74) | 0.76 (0.48, 1.19) | -25.5 (-54.1, 3.1) |
PHQ-2 score | |||||
 0-2 | 15.6 | 11.7 | 1.39 (0.83, 2.33) | 1.35 (1.00, 1.81)a | 29.8 (1.2, 58.3)a |
 3-6 | 23.4 | 14.9 | 1.75 (0.96, 3.20) | 1.39 (0.90, 2.15) | 33.9 (-0.8, 68.6) |
Concomitant antidepressants other than SSRI/SNRI | |||||
 Yes | 31.3 | 5.6 | 7.67 (6.93, 8.49)a | 3.74 (1.55, 9.07)a | 155.3 (153.3, 157.3)a |
 No | 16.1 | 12.0 | 1.41 (0.94, 2.13) | 1.34 (1.04, 1.73)a | 29.5 (5.1, 53.8)a |
Underlying cognitive impairment | |||||
 Yes | 21.4 | 15.5 | 1.49 (0.99, 2.24) | 1.06 (0.80, 1.42) | 6.3 (-18.1, 30.7) |
 No | 15.4 | 10.7 | 1.51 (0.89, 2.57) | 1.49 (1.10, 2.03)a | 39.9 (9.9, 69.9)a |
Sensitivity analyses | |||||
 1:1 nearest neighbor PS matching | 16.4 | 11.8 | 1.46 (0.97, 2.20) | 1.27 (1.18, 1.37)a | 28.0 (5.1, 50.9)a |
 Removing comedications from PS estimation | 16.4 | 11.8 | 1.46 (0.97, 2.20) | 1.12 (1.05, 1.20)a | 22.0 (9.1, 34.8)a |